Welcome to our dedicated page for HeartSciences news (Ticker: HSCSW), a resource for investors and traders seeking the latest updates and insights on HeartSciences stock.
HeartSciences Inc. (HSCSW) generates news as a healthcare information technology and medical technology company focused on applying artificial intelligence to ECGs/EKGs. Its disclosures emphasize efforts to enhance the clinical utility of ECGs, support earlier detection of heart disease, and modernize ECG workflows through cloud-based software and AI-enabled devices.
News about HeartSciences frequently covers developments related to its MyoVista Insights platform and MyoVista wavECG device. The company reports on commercial milestones for MyoVista Insights, including early adopter deployments and its first commercial customer, as well as software updates such as the release of version 1.1, which it describes as enhancing usability, clinical interpretation, workflow efficiency, and interoperability across ECG devices.
Regulatory and clinical news items include announcements about FDA Breakthrough Device designation for an aortic stenosis ECG algorithm and the submission of the MyoVista wavECG device to the U.S. Food and Drug Administration for 510(k) premarket clearance. HeartSciences also issues updates on its AI-ECG algorithm pipeline, including plans for cloud-based algorithms delivered through MyoVista Insights.
Investors can also find coverage of financial results, capital-raising activities such as the company’s Regulation A offering and at-the-market program, and corporate governance updates reported in SEC filings and related press releases. For readers tracking HSCS and HSCSW, the news stream provides context on product development, regulatory progress, platform commercialization, and the company’s position within the emerging AI-ECG field.
Heart Test Laboratories, Inc., operating as HeartSciences (Nasdaq: HSCS; HSCSW), reported its fiscal 2023 Q3 results ending January 31, 2023. The company is advancing its AI-based ECG, MyoVista®, and has engaged in a multi-year collaboration with Rutgers University for algorithm development. HeartSciences strengthened its balance sheet with a $15 million equity facility and other financial maneuvers. However, the company reported no meaningful revenues for Q3, holding $1.9 million in cash as of January 31, 2023. The CEO emphasized the focus on FDA De Novo clearance and cash management to support ongoing operational goals.
Heart Test Laboratories, Inc., also known as HeartSciences (NASDAQ: HSCS; HSCSW), announced that CEO Andrew Simpson will appear on the Big Biz Show on February 7, 2023, at 11:45 a.m. PT. The show is nationally syndicated and will be broadcast on platforms including Fox Business and NBCUniversal. Simpson will discuss the MyoVista® device, which leverages AI to enhance ECG utility for early heart disease detection in at-risk patients. The MyoVista® aims to transform traditional ECGs into effective screening tools in front-line care settings, addressing significant limitations in heart disease identification.
HeartSciences (NASDAQ: HSCS; HSCSW) announced the granting of a patent in Israel (Patent No. 10-2490960) for its innovative AI-based ECG technology. This patent aims to enhance the ECG's effectiveness in detecting cardiac dysfunction, a significant issue given that cardiovascular diseases cause 17.9 million deaths annually worldwide.
CEO Andrew Simpson emphasized that the patent reinforces their intellectual property strategy, offering competitive advantages as they approach commercialization. Overall, the company holds 40 patents globally, with eight more pending, positioning it strongly in the medical technology market.
HeartSciences has been granted Korean Patent No. 10-2490960 for its MyoVista® Wavelet Technology, enhancing its intellectual property portfolio to a total of 39 patents worldwide, including nine in the US. This technology aims to improve ECGs by using AI for detecting left ventricular diastolic dysfunction, addressing a significant health issue, as cardiovascular diseases lead to 17.9 million deaths annually. With this patent, HeartSciences enhances its competitive edge in the global market, supporting its objective to transform ECGs into effective cardiac health screening tools.
Heart Test Laboratories, d/b/a HeartSciences (NASDAQ: HSCS; HSCSW), announced participation by CEO Andrew Simpson in the Healthcare IT Virtual Conference on January 25, 2023. The event, hosted by Maxim Group LLC and M-Vest, features a fireside chat with analyst Allen Klee at 11:30 a.m. ET. HeartSciences focuses on enhancing ECG effectiveness using AI technology to improve cardiac screening, especially in frontline settings. The MyoVista® wavECG is its first product candidate designed for FDA clearance, providing both conventional ECG and diagnostic information on cardiac dysfunction. For details, visit heartsciences.com.
Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) appointed David R. Wells to its Board of Directors effective December 28, 2022, following Patrick Kanouff's resignation. CEO Andrew Simpson praised Wells for his extensive finance and capital markets experience, particularly in medical technology and startups. With over 30 years in senior financial management, Wells previously served as CFO at ENDRA Life Sciences and GHS Investments, bringing valuable expertise as the company advances toward commercialization of its AI-enhanced ECG product, MyoVista®.
Heart Test Laboratories, operating as HeartSciences (NASDAQ: HSCS; HSCSW), provided a business update on December 16, 2022, indicating significant progress toward FDA De Novo resubmission of its MyoVista technology. The company has nearly finished patient enrollment for its pivotal validation study and aims for resubmission by fiscal year-end. HeartSciences also strengthened its intellectual property with new patents and received new CPT codes for AI-assisted ECG assessments. However, the company reported no meaningful revenues for Q2 2023, holding $3.1 million in cash.
Heart Test Laboratories, Inc., operating as HeartSciences (NASDAQ: HSCS; HSCSW), has announced a multi-year collaboration with Rutgers University to develop AI-based ECG algorithms. This partnership aims to enhance the clinical utility of ECGs for cost-effective heart disease detection. Dr. Partho P. Sengupta will lead the initiative leveraging Rutgers' extensive clinical data. The collaboration is expected to significantly speed up HeartSciences' product development pipeline. CEO Andrew Simpson highlights this as a step towards bringing advanced clinical capabilities to ECGs, affirming the company's leadership in cardiac innovation.
Heart Test Laboratories, Inc. (d/b/a HeartSciences) (NASDAQ: HSCS; HSCSW) will have CEO Andrew Simpson present at the 2022 RHK Disruptive Growth Conference on December 5-6, 2022, in New York City. The conference aims to showcase up to 50 growth companies to over 200 institutional and accredited investors. HeartSciences focuses on enhancing ECG technology through AI, with its MyoVista® wavECG device set to revolutionize cardiac screening. The company emphasizes improving healthcare delivery, especially in point-of-care settings.
Heart Test Laboratories, Inc., operating as HeartSciences (NASDAQ: HSCS; HSCSW), announced a study validating its MyoVista® technology in cardiac risk stratification. The independent research highlighted its AI-ECG algorithm's ability to predict major adverse cardiovascular events (MACE) effectively. The study involved 518 patients over 38 months and showed a significantly higher probability of identifying high-risk patients (21%) compared to low-risk (3%). Results align closely with traditional echo-based models, indicating strong potential for AI in clinical settings.
FAQ
What is the current stock price of HeartSciences (HSCSW)?
